PEDIATRICS Vol. 47 No. 2 February 1971, pp. 384-390
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Solomons, C. C.
Right arrow Articles by Pinney, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Solomons, C. C.
Right arrow Articles by Pinney, M.

THE USE OF BUFFERED L-ARGININE IN THE TREATMENT OF CYSTIC FIBROSIS

Clive C. Solomons Ph.D.1, Ernest K. Cotton M.D.1, Reuben Dubois M.B., B.S.1, and Margo Pinney R.N., B.S.1

1 Department of Pediatrics, University of Colorado Medical School, Denver, Colorado

Buffered L-arginine was administered to 22 patients with cystic fibrosis in an attempt to improve pulmonary function and fat absorption. Arginine was selected because of its low toxicity, ability to break hydrogen bonds, bind metal ions, and act as a detergent.

When arginine was administered by inhalation as an ultrasonicated mist to eight patients with chronic lung diseases, improvements occurred in vital capacity, thoracic gas volume, specific conductance, and arterial Po2. Oral administration of arginine to patients with predominantly gastrointestinal symptomatology resulted in rapid relief of abdominal pain, weight gain in all the patients treated in this fashion, and improved fat absorption in 11 out of 14 patients. There were no important side effects attributable to the inhalation or oral administration of buffered arginine.

Submitted on May 20, 1970
Accepted on October 1, 1970




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
H. Grasemann, F. Kurtz, and F. Ratjen
Inhaled L-Arginine Improves Exhaled Nitric Oxide and Pulmonary Function in Patients with Cystic Fibrosis
Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 208 - 212.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. Borriello, L. Richards, G. D. Ehrlich, and P. S. Stewart
Arginine or Nitrate Enhances Antibiotic Susceptibility of Pseudomonas aeruginosa in Biofilms
Antimicrob. Agents Chemother., January 1, 2006; 50(1): 382 - 384.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. R. Morris, S. M. Morris Jr., W. Hagar, J. van Warmerdam, S. Claster, D. Kepka-Lenhart, L. Machado, F. A. Kuypers, and E. P. Vichinsky
Arginine Therapy: A New Treatment for Pulmonary Hypertension in Sickle Cell Disease?
Am. J. Respir. Crit. Care Med., July 1, 2003; 168(1): 63 - 69.
[Abstract] [Full Text] [PDF]